Thomas X. Neenan Ph.D.
is a Boston based entrepreneur whose most recent venture was as Founder and CTO of Sideris Pharmaceuticals Inc.
, a developer of novel chelators for the treatment of diseases of iron overload.
raised $32M in equity financing and completed an option deal worth up to $300M with Novartis Pharmaceuticals
in Oct. 2013.
Prior to Sideris, Dr. Neenan served in founder or senior management role at several materials and polymer focused companies including Viscus Biologics LLC (xenografts), Proxy Biomedical (Galway, Ireland) (polymeric surgical materials), Warwick Effect Polymers (Coventry, UK) (controlled free radical polymerization for consumer and biomedical applications) and Trine Pharmaceuticals (gastrointestinal drugs).
Previously, Dr. Neenan held positions of increasing responsibility, including Vice-President of New Technology Development at Geltex Pharmaceuticals, a polymer drug company acquired by Genzyme for $1.1B.
Dr. Neenan holds a B.Sc (Hons) from University College Dublin.
He received his Ph.D. in inorganic chemistry from the Pennsylvania State University, and was a Fellow at Harvard University.
is the author of 60+ publications and holds 40+ US and international patents.
Dr. Neenan currently serves on the Board of Directors of Sun BioPharma Inc., a privately financed pancreatic oncology company, and as an advisor to Quad Technologies Inc., a development stage company specializing in cell and protein separations science.